According to a recent LinkedIn post from RunSafe Security, the company is spotlighting a webinar focused on cybersecurity risks emerging from AI-assisted software development in medical devices. The event features CEO Joe Saunders and Brad Tenenholtz of Splyce LLC, and is positioned around topics such as AI-generated code, open-source dependencies, and regulatory compliance exposure.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests RunSafe is aligning its expertise with a high-stakes, regulated vertical where software integrity and supply-chain security are increasingly critical. For investors, this emphasis on medical device cybersecurity could indicate a strategic push into healthcare and life sciences, potentially expanding the company’s addressable market.
By framing AI-enabled development as both an innovation driver and a risk vector, the content underscores growing demand for tools that manage vulnerabilities across complex software supply chains. If RunSafe’s solutions are perceived as effective in addressing these issues, the firm could benefit from rising security budgets among medical device manufacturers.
Featuring an external partner, Splyce LLC, may also point to a collaborative go-to-market strategy and ecosystem positioning. Such partnerships can enhance credibility, shorten sales cycles, and improve access to specialized customer segments, which may support revenue growth and strengthen RunSafe’s competitive stance in application and supply-chain security.